PT  - JOURNAL ARTICLE
AU  - Thompson, Mark G.
AU  - Burgess, Jefferey L.
AU  - Naleway, Allison L.
AU  - Tyner, Harmony
AU  - Yoon, Sarang K.
AU  - Meece, Jennifer
AU  - Olsho, Lauren E.W.
AU  - Caban-Martinez, Alberto J.
AU  - Fowlkes, Ashley L.
AU  - Lutrick, Karen
AU  - Groom, Holly C.
AU  - Dunnigan, Kayan
AU  - Odean, Marilyn J
AU  - Hegmann, Kurt
AU  - Stefanski, Elisha
AU  - Edwards, Laura J.
AU  - Schaefer-Solle, Natasha
AU  - Grant, Lauren
AU  - Ellingson, Katherine
AU  - Kuntz, Jennifer L.
AU  - Zunie, Tnelda
AU  - Thiese, Matthew S.
AU  - Ivacic, Lynn
AU  - Wesley, Meredith G.
AU  - Lamberte, Julie Mayo
AU  - Sun, Xiaoxiao
AU  - Smith, Michael E.
AU  - Phillips, Andrew L.
AU  - Groover, Kimberly D.
AU  - Yoo, Young M.
AU  - Gerald, Joe K.
AU  - Brown, Rachel T.
AU  - Herring, Meghan K.
AU  - Joseph, Gregory
AU  - Beitel, Shawn
AU  - Morrill, Tyler C.
AU  - Mak, Josephine
AU  - Rivers, Patrick
AU  - Poe, Brandon P.
AU  - Lynch, Brian
AU  - Zhou, Ying Tao
AU  - Zhang, Jing
AU  - Kelleher, Anna
AU  - Li, Yan
AU  - Dickerson, Monica
AU  - Hanson, Erika
AU  - Guenther, Kyley
AU  - Tong, Suxiang
AU  - Bateman, Allen
AU  - Reisdorf, Erik
AU  - Barnes, John
AU  - Azziz-Baumgartner, Eduardo
AU  - Hunt, Danielle R.
AU  - Arvay, Melissa L.
AU  - Kutty, Preeta
AU  - Fry, Alicia M.
AU  - Gaglani, Manjusha
TI  - Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines
AID  - 10.1101/2021.06.01.21257987
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.01.21257987
4099  - http://medrxiv.org/content/early/2021/06/03/2021.06.01.21257987.1.short
4100  - http://medrxiv.org/content/early/2021/06/03/2021.06.01.21257987.1.full
AB  - BACKGROUND Information is limited on messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection or attenuating disease when administered in real-world conditions.METHODS Prospective cohorts of 3,975 healthcare personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing during December 14, 2020—April 10 2021. Self-collected mid-turbinate nasal swabs were tested by qualitative and quantitative reverse-transcription–polymerase-chain-reaction (RT-PCR). VE was calculated as 100%×(1−hazard ratio); adjusted VE was calculated using vaccination propensity weights and adjustments for site, occupation, and local virus circulation.RESULTS SARS-CoV-2 was detected in 204 (5.1%) participants; 16 were partially (≥14 days post-dose-1 to 13 days after dose-2) or fully (≥14 days post-dose-2) vaccinated, and 156 were unvaccinated; 32 with indeterminate status (<14 days after dose-1) were excluded. Adjusted mRNA VE of full vaccination was 91% (95% confidence interval [CI]=76%–97%) against symptomatic or asymptomatic SARS-CoV-2 infection; VE of partial vaccination was 81% (95% CI=64%-90%). Among partially or fully vaccinated participants with SARS-CoV-2 infection, mean viral RNA load (Log10 copies/mL) was 40% lower (95% CI=16%-57%), the risk of self-reported febrile COVID-19 was 58% lower (Risk Ratio=0.42, 95% CI=0.18-0.98), and 2.3 fewer days (95% CI=0.8-3.7) were spent sick in bed compared to unvaccinated infected participants.CONCLUSIONS Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infections when administered in real-world conditions and attenuated viral RNA load, febrile symptoms, and illness duration among those with breakthrough infection despite vaccination.Competing Interest StatementAllison L. Naleway reported funding from Pfizer for a meningococcal B vaccine study unrelated to the submitted work. Kurt T. Hegmann serves at the Editor of the American College of Occupational and Environmental Medicine evidence-based practice guidelines. Matthew S. These reported grants and personal fees from Reed Group and the American College of Occupational and Environmental Medicine, outside the submitted work. Other authors have reported no conflicts of interest.Funding StatementFunding provided in whole or in part by federal funds from the National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention under contract numbers 75D30120R68013 awarded to Marshfield Clinic Research Laboratory, 75D30120C08379 to University of Arizona, and 75D30120C08150 awarded to Abt Associates, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the University of Arizona IRB as the single IRB for this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data will be available once all study objectives are met.